RY

161.73

+2.56%↑

TD

93.32

+1.91%↑

BMO

135.42

+2.9%↑

CM

94.74

+3.18%↑

BNS

69.28

+2.87%↑

RY

161.73

+2.56%↑

TD

93.32

+1.91%↑

BMO

135.42

+2.9%↑

CM

94.74

+3.18%↑

BNS

69.28

+2.87%↑

RY

161.73

+2.56%↑

TD

93.32

+1.91%↑

BMO

135.42

+2.9%↑

CM

94.74

+3.18%↑

BNS

69.28

+2.87%↑

RY

161.73

+2.56%↑

TD

93.32

+1.91%↑

BMO

135.42

+2.9%↑

CM

94.74

+3.18%↑

BNS

69.28

+2.87%↑

RY

161.73

+2.56%↑

TD

93.32

+1.91%↑

BMO

135.42

+2.9%↑

CM

94.74

+3.18%↑

BNS

69.28

+2.87%↑

Search

Hercules Capital Inc

Închisă

SectorFinanțe

14.76 4.02

Rezumat

Modificarea prețului

24h

Curent

Minim

14.19

Maxim

14.81

Indicatori cheie

By Trading Economics

Venit

-28M

91M

Vânzări

-12M

158M

P/E

Medie Sector

7.838

54.484

EPS

0.48

Randament dividend

11.29

Marjă de profit

57.578

Angajați

100

EBITDA

-3.5M

116M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+35.56% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

11.29%

4.92%

Următoarele câștiguri

30 apr. 2026

Data viitoare de dividende

19 mai 2026

Următoarea dată ex-dividende

12 mai 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

-389M

2.7B

Deschiderea anterioară

10.74

Închiderea anterioară

14.76

Sentimentul știrilor

By Acuity

50%

50%

171 / 441 Clasament în Finance

Scor tehnic

By Trading Central

Încredere

Neutral Evidence

Hercules Capital Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

31 mar. 2026, 23:31 UTC

Acțiuni populare

Stocks to Watch: Nike, RH, NCino

31 mar. 2026, 22:35 UTC

Câștiguri

Nike Guides for Sales Declines Ahead as Turnaround Plan Hits Snags -- 2nd Update

1 apr. 2026, 00:00 UTC

Achiziții, Fuziuni, Preluări

The Year Is Off to the Strongest Start for Big Deals Ever -- WSJ

31 mar. 2026, 23:50 UTC

Achiziții, Fuziuni, Preluări

Nxera Pharma: Partner Centessa Pharmaceuticals to Be Acquired by Lilly >LLY 4565.TO

31 mar. 2026, 23:43 UTC

Market Talk

Nikkei May Rise on Hopes for Iran War Ending Soon -- Market Talk

31 mar. 2026, 23:33 UTC

Market Talk
Evenimente importante

Gold Edges Higher on Signs of De-Escalating Middle East Tensions -- Market Talk

31 mar. 2026, 23:21 UTC

Câștiguri

Nike Stock Slides on Tariff Impact Despite Earnings Beat; Turnaround Continues -- Barrons.com

31 mar. 2026, 23:14 UTC

Market Talk
Câștiguri

Nike CEO Says Turnaround is Taking Longer Than He'd Like -- Market Talk

31 mar. 2026, 23:12 UTC

Market Talk

Aurelia's Cash Flow Strength Highlighted by New Financing Deal -- Market Talk

31 mar. 2026, 22:36 UTC

Câștiguri

China Vanke 2025 Loss Widens >000002.SZ

31 mar. 2026, 22:36 UTC

Câștiguri

China Vanke: Increase in Inventory Impariment Provision Among Factors Weighing On Results>000002.SZ

31 mar. 2026, 22:36 UTC

Câștiguri

China Vanke 2025 Loss CNY88.56B Vs. Loss CNY49.48B >000002.SZ

31 mar. 2026, 22:36 UTC

Câștiguri

China Vanke: Will Take Time to Resolve Issues Caused by High Debt Levels>000002.SZ

31 mar. 2026, 22:36 UTC

Câștiguri

China Vanke 2025 Rev CNY233.43B Vs. CNY343.18B >000002.SZ

31 mar. 2026, 21:46 UTC

Achiziții, Fuziuni, Preluări

Big Drug Companies Hunting for Deals Are Lowering Their Sights -- WSJ

31 mar. 2026, 21:36 UTC

Market Talk

West African Resources's Costs Higher Than Bull Expected -- Market Talk

31 mar. 2026, 21:35 UTC

Câștiguri

Nike Expects China Sales Down 20% in 4Q, CFO Says

31 mar. 2026, 21:35 UTC

Câștiguri

Nike Expects Modest Growth in North America, Offset by Declines in China, Converse Brand in 4Q, CFO Says

31 mar. 2026, 21:35 UTC

Câștiguri

Nike Forecasts 4Q Sales Down 2% to 4%, CFO Says

31 mar. 2026, 21:33 UTC

Achiziții, Fuziuni, Preluări

Biotechs Are a Healthy Growth Bet Thanks to M&A and New Drugs -- Barrons.com

31 mar. 2026, 21:33 UTC

Câștiguri

Nike Expects Sales Down Low-Single Digits From Now Through End of Calendar Year, CFO Says

31 mar. 2026, 21:32 UTC

Câștiguri

Nike Expects 1Q to Be Final Quarter Where Tariffs Continue to Be Year-Over-Year Headwind to Margins, CFO Says

31 mar. 2026, 21:28 UTC

Câștiguri

Nike Expects to End 4Q With Elevated Inventory, CFO Says

31 mar. 2026, 21:26 UTC

Câștiguri

Nike Increasingly Confident It Will Return to Balanced Growth in North America in Direct, Wholesale Channels, CFO Says

31 mar. 2026, 21:25 UTC

Câștiguri

Nike Expects Supply-Chain Changes to Pay Off Starting in Fiscal 2027, CFO Says

31 mar. 2026, 21:24 UTC

Market Talk
Câștiguri

Nike: Turnaround Plan Progressing at Different Rates -- Market Talk

31 mar. 2026, 21:22 UTC

Câștiguri

Nike CFO Expects Football Training and Basketball Will Return to Growth Over Next Few Quarters

31 mar. 2026, 21:22 UTC

Câștiguri

Nike's Sportswear Business Declined Low-Double Digits in 3Q, CFO Says

31 mar. 2026, 21:21 UTC

Câștiguri

Nike's Digital Channel Still Too Promotional, CFO Says

31 mar. 2026, 21:20 UTC

Câștiguri

Nike CEO: Converse Remains Important to Portfolio

Comparație

Modificare preț

Hercules Capital Inc Așteptări

Obiectiv de preț

By TipRanks

35.56% sus

Prognoză pe 12 luni

Medie 19.25 USD  35.56%

Maxim 25 USD

Minim 15 USD

În baza a 6 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruHercules Capital Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

6 ratings

4

Cumpărare

2

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

17.41 / 17.93Suport & Rezistență

Termen scurt

Neutral Evidence

Termen mediu

Strong Bearish Evidence

Termen lung

Bearish Evidence

Sentiment

By Acuity

171 / 441 Clasament în Finanțe

Sentimentul știrilor

Neutral

Volatilitate

Sub medie

Volumul știrilor (RCV)

Medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Hercules Capital Inc

Hercules Capital, Inc. is a business development company. The firm specializing in providing private equity, venture debt, and growth capital to privately held venture capital-backed companies at all stages of development from mid venture to expansion stage including select publicly listed companies and select special opportunity companies that require additional capital to fund acquisitions, recapitalizations and refinancing and established-stage companies. The firm provides growth capital financing solutions for capital extension; management buy-out and corporate spin-out financing solutions; company, asset specific, or intellectual property acquisition financing; convertible, subordinated and/or mezzanine loans; domestic and international corporate expansion; vendor financing; revenue acceleration by sales and marketing development, and manufacturing expansion. It provides asset-based financing with a focus on cash flow; accounts receivable facilities; equipment loans or leases; equipment acquisition; facilities build-out and/or expansion; working capital revolving lines of credit; inventory. The firm also provides bridge financing to IPO or mergers and acquisitions or technology acquisition; dividend recapitalizations and other sources of investor liquidity; cash flow financing to protect against share price volatility; competitor acquisition; pre-IPO financing for extra cash on the balance sheet; public company financing to continue asset growth and production capacity; short-term bridge financing; and strategic and intellectual property acquisition financings. It also focuses on customized financing solutions, emerging growth, mid venture, and late venture financing. The firm invests primarily in structured debt with warrants and, to a lesser extent, in senior debt and equity investments. The firm generally seeks to invest in companies that have been operating for at least six to 12 months prior to the date of their investment. It prefers to invest in technology, SaaS Finance, energy technology, sustainable
help-icon Live chat